AstraZeneca's key cholesterol drug Crestor has seen its market share growth in the United States stall, suggesting sales this year may struggle to meet forecasts, Citigroup analysts said on Friday.
Crestor's share of both newly written and total prescriptions has been broadly flat at 7.6 percent and 7.2 percent through 2007, as the growth of generic simvastatin continues unabated.
Here's a reminder of what Insider was writing about the Big C just over a year ago!
No comments:
Post a Comment